Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

BACKGROUND: Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether patients with low-volume (LV) disease benefit from early D. OBJECTIVE: T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Urol
Hlavní autoři: Gravis, Gwenaelle, Boher, Jean-Marie, Chen, Yu-Hui, Liu, Glenn, Fizazi, Karim, Carducci, Michael A., Oudard, Stephane, Joly, Florence, Jarrard, David M., Soulie, Michel, Eisenberger, Mario J., Habibian, Muriel, Dreicer, Robert, Garcia, Jorge A., Hussain, Maha H.M., Kohli, Manish, Vogelzang, Nicholas J., Picus, Joel, DiPaola, Robert, Sweeney, Christopher
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010352/
https://ncbi.nlm.nih.gov/pubmed/29475737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2018.02.001
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky